Renal cancer clinical trial pipeline is active with 75+ key pharma companies developing therapies.

From GlobeNewswire: 2024-09-24 13:00:00

Renal cancer clinical trial pipeline is robust with 75+ key pharma companies actively developing therapies. Global incidence is rising due to factors like smoking and obesity. Renal Cancer Pipeline Insight 2024 report by DelveInsight highlights 70+ active players developing 75+ pipeline therapies. Key companies include Genentech, Merck, and Arsenal Biosciences.

In July 2024, FDA granted Fast Track designation to ADI-270 for advanced clear cell renal cell carcinoma. AVEO Oncology’s Phase III trial for metastatic RCC did not meet primary endpoint. Adicet Bio’s ADI-270 Phase I trial for relapsed RCC initiated. Telix Pharmaceuticals submitted BLA for PET agent TLX250-CDx for ccRCC imaging.

Arsenal Biosciences dosed first patient in Phase I/II trial of AB-2100 for ccRCC, while Telix treated first patient in SAS for TLX250-CDx imaging. Adicet Bio started Phase I trial of ADI-270 for r/r RCC. Renal cancer treatments vary by stage and may include surgery, targeted therapy, and immunotherapy for better outcomes and survival rates.

Renal Cancer Pipeline Report by DelveInsight offers comprehensive insights on global pipeline with 70+ active players developing 75+ therapies. Key drugs include Atezolizumab, ALLO-316, and MK-4280A in different phases of clinical trials. Companies like Genentech and Arsenal Biosciences are working to advance renal cancer therapeutics domain. For more information, visit DelveInsight’s Renal Cancer Pipeline Report.



Read more at GlobeNewswire: Renal Cancer Clinical Trial Pipeline Appears Robust With